{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:23:13Z","timestamp":1791249793477,"version":"4.1.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Hospitalizations related to opioid use disorder (OUD) represent an opportunity to initiate medication for OUD (MOUD).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether starting MOUD after a hospitalization or emergency department (ED) visit is associated with the odds of fatal and nonfatal opioid overdose at 6 and 12 months.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based cohort study used data from the Oregon Comprehensive Opioid Risk Registry, which links all payer claims data to other administrative health datasets, for individuals aged 18 years or older who had diagnosis codes related to OUD recorded at an index ED visit or hospitalization from January 2017 to December 2019. Data were analyzed between May 2023 and January 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Receipt of MOUD within the 7 days after an OUD-related hospital visit.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was fatal or nonfatal overdose at 6 and 12 months after discharge. Sample characteristics, including age, sex, insurance plan, number of comorbidities, and opioid-related overdose events, were stratified by receipt or nonreceipt of MOUD within 7 days after an OUD-related hospital visit. A logistic regression model was used to investigate the association between receipt of MOUD and having an opioid overdose event.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included 22\u202f235 patients (53.1% female; 25.0% aged 25-39 years) who had an OUD-related hospital visit during the study period. Overall, 1184 patients (5.3%) received MOUD within 7 days of their ED visit or hospitalization. Of these patients, 683 (57.7%) received buprenorphine, 463 (39.1%) received methadone, and 46 (3.9%) received long-acting injectable naltrexone. Patients who received MOUD within 7 days after discharge had lower adjusted odds of fatal or nonfatal overdose at 6 months compared with those who did not (adjusted odds ratio [AOR], 0.63; 95% CI, 0.41-0.97). At 12 months, there was no difference in adjusted odds of fatal or nonfatal overdose between these groups (AOR, 0.79; 95% CI, 0.58-1.08). Patients had a lower risk of fatal or nonfatal overdose at 6 months associated with buprenorphine use (AOR, 0.50; 95% CI, 0.27-0.95) but not with methadone use (AOR, 0.57; 95% CI, 0.28-1.17).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of individuals with an OUD-related hospital visit, initiation of MOUD was associated with reduced odds of opioid-related overdose at 6 months. Hospitals should consider implementing programs and protocols to offer initiation of MOUD to patients with OUD who present for care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.23954","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T11:02:38Z","timestamp":1721646158000},"page":"e2423954","source":"Crossref","is-referenced-by-count":41,"title":["Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit"],"prefix":"10.1001","volume":"7","author":[{"given":"Scott G.","family":"Weiner","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacey","family":"Little","sequence":"additional","affiliation":[{"name":"Comagine Health, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiah","family":"Yoo","sequence":"additional","affiliation":[{"name":"Comagine Health, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana P.","family":"Flores","sequence":"additional","affiliation":[{"name":"Comagine Health, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi","family":"Hildebran","sequence":"additional","affiliation":[{"name":"Comagine Health, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagan A.","family":"Wright","sequence":"additional","affiliation":[{"name":"Oregon Health Authority, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"Ritter","sequence":"additional","affiliation":[{"name":"Brandeis University, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"El Ibrahimi","sequence":"additional","affiliation":[{"name":"Comagine Health, Portland, Oregon"},{"name":"School of Public Health, University of Nevada, Las Vegas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"issue":"3","key":"zoi240751r3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/infdis\/jiz133","article-title":"Opioids and infectious diseases: a converging public health crisis.","volume":"220","author":"Schwetz","year":"2019","journal-title":"J Infect Dis"},{"issue":"12","key":"zoi240751r4","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1097\/CCM.0000000000005141","article-title":"Epidemiology, outcomes, and trends of patients with sepsis and opioid-related hospitalizations in U.S. hospitals.","volume":"49","author":"Alrawashdeh","year":"2021","journal-title":"Crit Care Med"},{"issue":"9","key":"zoi240751r5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/jhm.v17.9","article-title":"Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: a systematic review of existing guidelines.","volume":"17","author":"Calcaterra","year":"2022","journal-title":"J Hosp Med"},{"issue":"3","key":"zoi240751r6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.annemergmed.2021.04.023","article-title":"Consensus recommendations on the treatment of opioid use disorder in the emergency department.","volume":"78","author":"Hawk","year":"2021","journal-title":"Ann Emerg Med"},{"issue":"8","key":"zoi240751r7","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"4","key":"zoi240751r8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/ADM.0000000000000499","article-title":"Predictors for 30-day and 90-day hospital readmission among patients with opioid use disorder.","volume":"13","author":"Moreno","year":"2019","journal-title":"J Addict Med"},{"issue":"6","key":"zoi240751r9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.12788\/jhm.3591","article-title":"Hospital buprenorphine program for opioid use disorder is associated with increased inpatient and outpatient addiction treatment.","volume":"16","author":"Christian","year":"2021","journal-title":"J Hosp Med"},{"issue":"11","key":"zoi240751r10","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s11606-022-07618-x","article-title":"A taxonomy of hospital-based addiction care models: a scoping review and key informant interviews.","volume":"37","author":"Englander","year":"2022","journal-title":"J Gen Intern Med"},{"key":"zoi240751r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100114","article-title":"Initiation of medication for opioid use disorder across a health system: A retrospective analysis of patient characteristics and inpatient outcomes.","volume":"5","author":"O\u2019Rourke","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"12","key":"zoi240751r12","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1007\/s11606-019-05251-9","article-title":"Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: a propensity-matched analysis.","volume":"34","author":"Englander","year":"2019","journal-title":"J Gen Intern Med"},{"key":"zoi240751r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103525","article-title":"Simulating the impact of addiction consult services in the context of drug supply contamination, hospitalizations, and drug-related mortality.","volume":"100","author":"King","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"11","key":"zoi240751r14","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/add.v112.11","article-title":"Cost-effectiveness of emergency department-initiated treatment for opioid dependence.","volume":"112","author":"Busch","year":"2017","journal-title":"Addiction"},{"key":"zoi240751r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.? a yearly assessment from 2010 to 2019.","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"12","key":"zoi240751r16","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.2105\/AJPH.2015.302885","article-title":"Leaving the hospital against medical advice among people who use illicit drugs: a systematic review.","volume":"105","author":"Ti","year":"2015","journal-title":"Am J Public Health"},{"issue":"10","key":"zoi240751r17","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s11606-023-08059-w","article-title":"Association of early opioid withdrawal treatment strategy and patient-directed discharge among hospitalized patients with opioid use disorder.","volume":"38","author":"Alrawashdeh","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"7","key":"zoi240751r18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/pds.v30.7","article-title":"Linkage of public health and all payer claims data for population-level opioid research.","volume":"30","author":"Hallvik","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi240751r19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"11","key":"zoi240751r20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"4","key":"zoi240751r22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/ADM.0000000000000915","article-title":"Causes of death in the 12 months after hospital discharge among patients with opioid use disorder.","volume":"16","author":"King","year":"2022","journal-title":"J Addict Med"},{"issue":"1","key":"zoi240751r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45691","article-title":"Factors associated with opioid overdose after an initial opioid prescription.","volume":"5","author":"Weiner","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi240751r24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMp2204687","article-title":"Hospital standards of care for people with substance use disorder.","volume":"387","author":"Englander","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi240751r25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.annemergmed.2019.04.020","article-title":"One-year mortality of patients after emergency department treatment for nonfatal opioid overdose.","volume":"75","author":"Weiner","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"1","key":"zoi240751r27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13033-023-00601-x","article-title":"Shifting drug markets in North America - a global crisis in the making?","volume":"17","author":"Meyer","year":"2023","journal-title":"Int J Ment Health Syst"},{"key":"zoi240751r28","doi-asserted-by":"publisher","first-page":"m772","DOI":"10.1136\/bmj.m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"issue":"16","key":"zoi240751r29","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial.","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"zoi240751r30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s11606-017-3993-2","article-title":"Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: outcomes during and after intervention.","volume":"32","author":"D\u2019Onofrio","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"6","key":"zoi240751r31","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"zoi240751r32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/ADM.0000000000001246","article-title":"Dispensing methadone at hospital discharge: one hospital\u2019s approach to implementing the \u201c72-hour rule\u201d change.","volume":"18","author":"Skogrand","year":"2024","journal-title":"J Addict Med"},{"issue":"5","key":"zoi240751r33","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s11606-024-08670-5","article-title":"Post-hospitalization care transition strategies for patients with substance use disorders: a narrative review and taxonomy.","volume":"39","author":"Incze","year":"2024","journal-title":"J Gen Intern Med"},{"issue":"4","key":"zoi240751r34","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.japh.2023.04.029","article-title":"Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility.","volume":"63","author":"Ostrach","year":"2023","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"5","key":"zoi240751r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16089","article-title":"Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US.","volume":"6","author":"Weiner","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi240751r36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/15563650.2022.2032730","article-title":"Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl.","volume":"60","author":"Spadaro","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"issue":"10","key":"zoi240751r37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/jhm.v18.10","article-title":"Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage.","volume":"18","author":"Calcaterra","year":"2023","journal-title":"J Hosp Med"},{"key":"zoi240751r2","volume-title":"Healthcare Cost and Utilization Project (HCUP) Statistical Briefs","author":"Owens","year":"2020"},{"key":"zoi240751r1","unstructured":"Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP) fast stats. Accessed May 22, 2024. https:\/\/datatools.ahrq.gov\/hcup-fast-stats\/"},{"key":"zoi240751r21","unstructured":"Davis? J, Sabel? J, Wright? D, Slavova? S. Epi tool to analyze overdose death data. Council of State and Territorial Epidemiologists. March 13, 2015. Accessed May 22, 2024. https:\/\/www.cste.org\/blogpost\/1084057\/211072\/Epi-Tool-to-Analyze-Overdose-Death-Data"},{"key":"zoi240751r26","unstructured":"US Customs and Border Protection. Drug seizure statistics. 2022. Accessed May 22, 2024. https:\/\/www.cbp.gov\/newsroom\/stats\/drug-seizure-statistics"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2821275\/weiner_2024_oi_240751_1720631632.54421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T11:02:42Z","timestamp":1721646162000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2821275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.23954","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}